体外大肠直肠癌筛检测试市场规模、份额、成长分析（按测试类型、最终用户、按地区）- 产业预测，2025-2032 年

2023年外部大肠癌筛检市场规模将为237.9亿美元，预测期内（2025-2032年）复合年增长率为11.1%，从2024年的264.3亿美元增至2032年的718亿美元。将成长至8000万美元。

由于大肠直肠癌病例的增加和创新基因检测方法的引入，体外结直肠癌筛检市场预计将显着增长。这些测试包括各种有助于早期发现大肠直肠癌的微创筛检选项，例如癒创木脂 FOB粪便检验、甲基化基因测定和大便潜血试验。这些测试是使用先进的体外技术和成像系统进行的，使其适合在诊所、医院和诊断实验室中使用。此外，消费者对使用 DNA 和遗传生物标记进行先进测试的需求不断增加，加上政府法规强制进行癌症筛检，预计将在未来几年推动这一市场领域的发展。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 案例研究
• 技术评估
• 监管环境
• 管道分析
• 疾病流行病学

外部大肠癌筛检测试市场规模：依测试类型

• 市场概况
• 大便潜血试验
  • 癒创木脂 FOB粪便检验
  • 免疫Fob凝集试验
  • 侧流免疫FOB测试
  • 免疫福布 ELISA 测试
• 生物标记测试
  • 肿瘤M2-Pk粪便检验
  • 转铁蛋白测定
• CRC DNA筛检测试
  • 甲基化基因检测
• 小组 DNA 测试

外部大肠癌筛检测试市场规模：按最终用户划分

• 市场概况
• 医院
• 诊所
• 诊断实验室
• 门诊手术中心

体外大肠直肠癌筛检测试市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Abbott Laboratories
• Beckman Coulter Inc
• Eiken Chemical Co., Ltd.
• Epigenomics
• Sysmex Corporation
• Siemens Healthcare GmbH
• Quest Diagnostics Incorporated
• OncoCyte Corporation
• Merck KGaA
• Immunostics Inc.
• Kyowa Kirin Co. Ltd.
• Randox Laboratories Ltd.
• R-Biopharm AG
• Bio-Rad Laboratories, Inc
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Genomic Health, Inc
• Hologic, Inc.
• Illumina, Inc.
• Invitae Corporation

结论和建议

In-Vitro Colorectal Cancer Screening Tests Market size was valued at USD 23.79 Billion in 2023 and is poised to grow from USD 26.43 Billion in 2024 to USD 71.88 Billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).

The market for in-vitro colorectal cancer screening tests is poised for significant growth, driven by increasing incidences of colon and rectal cancers and the introduction of innovative genetic testing methods. These tests encompass a variety of screening options such as guaiac FOB stool tests, methylated gene assays, and faecal occult blood tests, which are minimally invasive and facilitate the early detection of colorectal cancer. They operate through advanced in-vitro techniques that utilize imaging systems, making them suitable for implementation in clinics, hospitals, and diagnostics laboratories. Moreover, supportive government regulations mandating cancer screenings, alongside heightened consumer demand for advanced tests leveraging DNA and genetic biomarkers, further bolster this market segment's expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the In-Vitro Colorectal Cancer Screening Tests market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

In-Vitro Colorectal Cancer Screening Tests Market Segmental Analysis

Global In-Vitro Colorectal Cancer Screening Tests Market is segmented by test type, end user and region. Based on test type, the market is segmented into fecal occult blood tests, biomarker tests and CRC DNA screening tests. Based on end user, the market is segmented into hospitals, clinics, diagnostics laboratories and ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the In-Vitro Colorectal Cancer Screening Tests Market

The In-Vitro Colorectal Cancer Screening Tests market is experiencing notable growth driven by several key factors. The increasing incidence of colorectal cancer, influenced by an ageing population, unhealthy lifestyle choices, and rising diabetes rates, is propelling demand. Furthermore, heightened awareness of these screening tests, coupled with the widespread use of biomarkers, is contributing to market expansion. The desire for less invasive diagnostic methods and recent innovations in the field are expected to boost demand further. Additionally, awareness of the rising prevalence of colorectal cancer in younger populations and regulatory requirements for screening are also supporting market growth, allowing consumers to choose from various screening options tailored to individual needs.

Restraints in the In-Vitro Colorectal Cancer Screening Tests Market

The in-vitro colorectal cancer screening tests market may face several hindrances that could impede its growth. Key challenges include a shortage of skilled personnel and established screening protocols in developing countries, which limit effective implementation. Additionally, the insufficient reimbursement frameworks for in-vitro colorectal cancer testing further constrain market expansion. The Asia-Pacific region, in particular, is grappling with a significant deficit of qualified medical professionals, exacerbated by an aging population and increased physician workloads. Furthermore, the absence of supportive policies and initiatives aimed at raising awareness and encouraging the utilization of these tests may also hinder market development.

Market Trends of the In-Vitro Colorectal Cancer Screening Tests Market

The In-Vitro Colorectal Cancer Screening Tests market is witnessing significant growth driven by an alarming increase in colorectal cancer incidence among populations worldwide. Heightened public awareness surrounding the benefits of early detection and timely intervention further fuels this expansion. Technological advancements, particularly the integration of genetic testing into screening processes, are revolutionizing the market, facilitating not only early diagnosis but also the development of tailored treatment protocols. These innovations enhance the ability to curb the proliferation of cancerous cells, thereby reducing associated health risks. Collectively, these dynamics position the In-Vitro colorectal cancer screening segment for robust growth in the foreseeable future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Technology Assessment
• Regulatory Landscape
• Pipeline Analysis
• Disease Epidemiology

Global In-Vitro Colorectal Cancer Screening Tests Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Fecal Occult Blood Tests
  • Guaiac Fob Stool Test
  • Immuno-Fob Agglutination Test
  • Lateral Flow Immuno-Fob Test
  • Immuno-Fob Elisa Test
• Biomarker Tests
  • Tumor M2-Pk Stool Test
  • Transferrin Assays
• CRC DNA Screening Tests
  • Methylated Gene Testing
• Panel DNA Tests

Global In-Vitro Colorectal Cancer Screening Tests Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Diagnostics Laboratories
• Ambulatory Surgical Centers

Global In-Vitro Colorectal Cancer Screening Tests Market Size & CAGR (2025-2032)

• North America (Test Type, End User)
  • US
  • Canada
• Europe (Test Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eiken Chemical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epigenomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthcare GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OncoCyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunostics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R-Biopharm AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health, Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations